Standout Papers

Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC 2021 2026 2022 2024168
  1. Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC (2021)
    Tianqing Chu, Runbo Zhong et al. Journal of Thoracic Oncology

Immediate Impact

1 by Nobel laureates 58 standout
Sub-graph 1 of 24

Citing Papers

The emerging role of lactate in tumor microenvironment and its clinical relevance
2024 Standout
Bispecific and multispecific antibodies in oncology: opportunities and challenges
2024 Standout
2 intermediate papers

Works of Yuchen Han being referenced

Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC
2021 Standout
STAT3/LINC00671 axis regulates papillary thyroid tumor growth and metastasis via LDHA-mediated glycolysis
2021

Author Peers

Author Last Decade Papers Cites
Yuchen Han 405 354 302 78 844
Yota Yasumizu 346 310 399 77 879
Seiichi Kakegawa 557 369 216 52 900
Tetsukan Woo 364 350 370 42 864
Andreas M. Luebke 302 244 328 48 791
Alberto Servetto 257 377 490 55 847
Pietro De Placido 376 461 229 49 764
Elvire Pons‐Tostivint 337 448 233 46 735
Liwen Xiong 464 303 309 58 789
Guoshuang Shen 344 504 292 57 945
Hideaki Mitsui 284 316 387 47 846

All Works

Loading papers...

Rankless by CCL
2026